ValuEngine cut shares of Mylan N.V. (NASDAQ:MYL) from a buy rating to a hold rating in a report issued on Wednesday.
MYL has been the topic of several other reports. Cowen and Company restated a market perform rating and set a $43.00 price target (down from $55.00) on shares of Mylan N.V. in a research note on Sunday, May 21st. Zacks Investment Research lowered Mylan N.V. from a hold rating to a sell rating in a research note on Monday, May 15th. Guggenheim restated a neutral rating on shares of Mylan N.V. in a research note on Friday, March 3rd. Vetr lowered Mylan N.V. from a strong-buy rating to a buy rating and set a $44.68 price target on the stock. in a research note on Tuesday, February 14th. Finally, Leerink Swann restated an outperform rating and set a $52.00 price target on shares of Mylan N.V. in a research note on Monday, March 6th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of Buy and an average price target of $50.77.
Mylan N.V. (NASDAQ MYL) opened at 37.23 on Wednesday. Mylan N.V. has a 52 week low of $33.60 and a 52 week high of $50.40. The company has a market capitalization of $19.95 billion, a price-to-earnings ratio of 37.19 and a beta of 1.23. The company has a 50 day moving average of $38.54 and a 200 day moving average of $39.04.
Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings results on Wednesday, May 10th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.01. Mylan N.V. had a return on equity of 23.69% and a net margin of 4.59%. The firm had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same period in the previous year, the company posted $0.76 earnings per share. The company’s quarterly revenue was up 24.1% compared to the same quarter last year. On average, equities analysts forecast that Mylan N.V. will post $5.19 EPS for the current fiscal year.
In other Mylan N.V. news, President Rajiv Malik sold 25,000 shares of the company’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the transaction, the president now owns 799,855 shares of the company’s stock, valued at approximately $31,994,200. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Laboratories Abbott sold 44,000,000 shares of the company’s stock in a transaction on Thursday, March 23rd. The stock was sold at an average price of $41.60, for a total value of $1,830,400,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,035,000 shares of company stock worth $1,831,800,000. Company insiders own 0.69% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP boosted its stake in shares of Mylan N.V. by 2.6% in the first quarter. Wellington Management Group LLP now owns 46,373,108 shares of the company’s stock valued at $1,808,088,000 after buying an additional 1,165,852 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Mylan N.V. by 3,447.5% in the first quarter. BlackRock Inc. now owns 38,822,643 shares of the company’s stock valued at $1,513,696,000 after buying an additional 37,728,274 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Mylan N.V. by 3.9% in the first quarter. Vanguard Group Inc. now owns 29,348,816 shares of the company’s stock valued at $1,144,310,000 after buying an additional 1,090,791 shares during the last quarter. State Street Corp boosted its stake in shares of Mylan N.V. by 1.2% in the first quarter. State Street Corp now owns 20,176,564 shares of the company’s stock valued at $786,700,000 after buying an additional 234,521 shares during the last quarter. Finally, Pzena Investment Management LLC acquired a new stake in shares of Mylan N.V. during the first quarter valued at approximately $283,158,000. Institutional investors own 69.89% of the company’s stock.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.